Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Stenocare A/S is a company specializing in the development, cultivation, production, and distribution of medical cannabis products. Operating primarily in the healthcare sector, Stenocare focuses on providing quality-controlled cannabis oil for medical use, catering to patients across various therapeutic areas including chronic pain, multiple sclerosis, and more. The company emphasizes strict compliance with regulatory standards to ensure the safety and efficacy of their products. With a mission to help improve patients' quality of life, Stenocare A/S plays a significant role in the burgeoning medical cannabis industry, which continues to grow in importance as acceptance for alternative treatments expands globally. Headquartered in Denmark, the company collaborates with international partners to enhance its distribution network and product offerings, thereby strengthening its position in the European medical cannabis market.
DKK 0.13
+DKK 0.00 (+0.38%)
EOD Jul 1, 2026
The business is unprofitable at the operating level (-25.26% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 214.5%, still solid. Margins contracted 198.0pp, which offsets some of the top-line progress.
ROIC dropped from 15.44% to -18.18%, capital efficiency is deteriorating. Negative free cash flow of -DKK 7M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
DKK 9M
▲ +214.5% YoY
Net Income (TTM)
-DKK 855K
▲ +93.1% YoY
Op. Margin
-3.25%
▼ -198.0pp YoY
ROIC
-18.18%
▼ -33.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-DKK 3M
▼ -0.3% YoY
Op. Cash Flow (TTM)
-DKK 859K
▲ +58.8% YoY
Net Debt
DKK 1M
Cash & Equiv.
DKK 787K
3Y CAGR: +16.1%
Continue Research
Stenocare A/S (STENO.XCSE)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Stenocare A/S scores 30/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Stenocare A/S scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -3.3% operating margin and a -18.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh STENO.XCSE's valuation and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.